Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | Pomoč | SLO | ENG

Naslov:The role of plasmalemma vesicle-associated protein in pathological breakdown of blood-brain and blood-retinal barriers : potential novel therapeutic target for cerebral edema and diabetic macular edema
Avtorji:ID Bosma, Esmeralda K. (Avtor)
ID Noorden, Cornelis J. F. van (Avtor)
ID Schlingemann, Reinier O. (Avtor)
ID Klaassen, Ingeborg (Avtor)
Datoteke:URL URL - Izvorni URL, za dostop obiščite https://fluidsbarrierscns.biomedcentral.com/articles/10.1186/s12987-018-0109-2
 
.pdf PDF - Predstavitvena datoteka, prenos (1,52 MB)
MD5: 9CEB243A839AFD3AB02F91CEA7D06A49
 
URL URL - Izvorni URL, za dostop obiščite https://doi.org/10.1186/s12987-018-0109-2
 
Jezik:Angleški jezik
Tipologija:1.02 - Pregledni znanstveni članek
Organizacija:Logo NIB - Nacionalni inštitut za biologijo
Povzetek:Breakdown of the blood–brain barrier (BBB) or inner blood–retinal barrier (BRB), induced by pathologically elevated levels of vascular endothelial growth factor (VEGF) or other mediators, can lead to vasogenic edema and significant clinical problems such as neuronal morbidity and mortality, or vision loss. Restoration of the barrier function with corticosteroids in the brain, or by blocking VEGF in the eye are currently the predominant treatment options for brain edema and diabetic macular edema, respectively. However, corticosteroids have side effects, and VEGF has important neuroprotective, vascular protective and wound healing functions, implying that long-term anti-VEGF therapy may also induce adverse effects. We postulate that targeting downstream effector proteins of VEGF and other mediators that are directly involved in the regulation of BBB and BRB integrity provide more attractive and safer treatment options for vasogenic cerebral edema and diabetic macular edema. The endothelial cell-specific protein plasmalemma vesicle-associated protein (PLVAP), a protein associated with trans-endothelial transport, emerges as candidate for this approach. PLVAP is expressed in a subset of endothelial cells throughout the body where it forms the diaphragms of caveolae, fenestrae and trans-endothelial channels. However, PLVAP expression in brain and eye barrier endothelia only occurs in pathological conditions associated with a compromised barrier function such as cancer, ischemic stroke and diabetic retinopathy. Here, we discuss the current understanding of PLVAP as a structural component of endothelial cells and regulator of vascular permeability in health and central nervous system disease. Besides providing a perspective on PLVAP identification, structure and function, and the regulatory processes involved, we also explore its potential as a novel therapeutic target for vasogenic cerebral edema and retinal macular edema.
Ključne besede:plasmalemma vesicle-associated protein, blood-brain barrier, blood-retinal barrier, cerebral edema, diabetic macular edema
Status publikacije:Objavljeno
Verzija publikacije:Objavljena publikacija
Datum objave:20.09.2018
Leto izida:2018
Št. strani:str. -17
Številčenje:Vol. 15, article no. ǂ24
PID:20.500.12556/DiRROS-20135 Novo okno
UDK:577
ISSN pri članku:2045-8118
DOI:10.1186/s12987-018-0109-2 Novo okno
COBISS.SI-ID:40461829 Novo okno
Opomba:Soavtorji: Cornelis J. F. van Noorden, Reinier O. Schlingemann, Ingeborg Klaassen; Nasl. z nasl. zaslona; Opis vira z dne 9. 3. 2020;
Datum objave v DiRROS:06.08.2024
Število ogledov:269
Število prenosov:206
Metapodatki:XML DC-XML DC-RDF
:
Kopiraj citat
  
Objavi na:Bookmark and Share


Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Gradivo je del revije

Naslov:Fluids and barriers of the CNS
Skrajšan naslov:Fluids barriers CNS
Založnik:BioMed Central
ISSN:2045-8118
COBISS.SI-ID:518947097 Novo okno

Gradivo je financirano iz projekta

Financer:Drugi - Drug financer ali več financerjev
Program financ.:Dutch Diabetes Fund
Številka projekta:2014.00.1784

Financer:Drugi - Drug financer ali več financerjev
Program financ.:Landelijke Stichting voor Blinden en Slechtzienden, Novartis Fonds and MaculaFonds
Številka projekta:UitZicht 2014-33

Financer:Drugi - Drug financer ali več financerjev
Program financ.:the Nederlandse Vereniging ter Verbetering van het Lot der Blinden, Rotterdamse Stichting Blindenbelangen
Številka projekta:B20140050

Financer:Drugi - Drug financer ali več financerjev
Program financ.:the Edmond en Marianne Blaauw Fonds voor Oogheelkunde

Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.

Sekundarni jezik

Jezik:Slovenski jezik
Ključne besede:biokemija, protein, povezan s plazmalemmo, krvno-možganska ovira, cerebralni edem, diabetični makularni edem


Nazaj